scholarly journals Neoadjuvant intraperitoneal chemotherapy followed by radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Bianca Escorel Costa Fava ◽  
Wilson Luiz da Costa ◽  
Maria Luiza L. Medeiros ◽  
Marina Sonagli ◽  
Héber Salvador de Castro Ribeiro ◽  
...  
2017 ◽  
Vol 28 ◽  
pp. iii42
Author(s):  
Masahiro Yoshida ◽  
Yasushi Tsuji ◽  
Maki Tanakamaru ◽  
Naoka Okamura ◽  
Junko Sugiyama ◽  
...  

2021 ◽  
Vol 47 (2) ◽  
pp. e53
Author(s):  
Elisabetta Marino ◽  
Maria Cristina Vannoni ◽  
Emanuele Rosati ◽  
Stefano Avenia ◽  
Luigina Graziosi ◽  
...  

2016 ◽  
Vol 42 (10) ◽  
pp. S212-S213
Author(s):  
F. Ferrara ◽  
D. Marrelli ◽  
L. De Franco ◽  
G. Di Mare ◽  
C. Voglino ◽  
...  

2019 ◽  
Vol 37 (23) ◽  
pp. 2028-2040 ◽  
Author(s):  
Pierre-Emmanuel Bonnot ◽  
Guillaume Piessen ◽  
Vahan Kepenekian ◽  
Evelyne Decullier ◽  
Marc Pocard ◽  
...  

PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to compare outcomes between CRS-HIPEC versus CRS alone (CRSa) among patients with PMs from GC. PATIENTS AND METHODS From prospective databases, we identified 277 patients with PMs from GC who were treated with complete CRS with curative intent (no residual nodules > 2.5 mm) at 19 French centers from 1989 to 2014. Of these patients, 180 underwent CRS-HIPEC and 97 CRSa. Tumor burden was assessed using the peritoneal cancer index. A Cox proportional hazards regression model with inverse probability of treatment weighting (IPTW) based on propensity score was used to assess the effect of HIPEC and account for confounding factors. RESULTS After IPTW adjustment, the groups were similar, except that median peritoneal cancer index remained higher in the CRS-HIPEC group (6 v 2; P = .003). CRS-HIPEC improved overall survival (OS) in both crude and IPTW models. Upon IPTW analysis, in CRS-HIPEC and CRSa groups, median OS was 18.8 versus 12.1 months, 3- and 5-year OS rates were 26.21% and 19.87% versus 10.82% and 6.43% (adjusted hazard ratio, 0.60; 95% CI, 0.42 to 0.86; P = .005), and 3- and 5-year recurrence-free survival rates were 20.40% and 17.05% versus 5.87% and 3.76% ( P = .001), respectively; the groups did not differ regarding 90-day mortality (7.4% v 10.1%, respectively; P = .820) or major complication rate (53.7% v 55.3%, respectively; P = .496). CONCLUSION Compared with CRSa, CRS-HIPEC improved OS and recurrence-free survival, without additional morbidity or mortality. When complete CRS is possible, CRS-HIPEC may be considered a valuable therapy for strictly selected patients with limited PMs from GC.


Sign in / Sign up

Export Citation Format

Share Document